Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) …
SM Moe, GM Chertow, PS Parfrey, Y Kubo, GA Block… - Circulation, 2015 - Am Heart Assoc
Background—Patients with kidney disease have disordered bone and mineral metabolism,
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE …
Evaluation of Cinacalcet HCl Therapy to Lower … - …, 2015 - experts.nebraska.edu
Background. Patients with kidney disease have disordered bone and mineral metabolism,
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
[PDF][PDF] Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis
SM Moe, GM Chertow, PS Parfrey, Y Kubo, GA Block… - Circulation, 2015 - volgmed.ru
Background—Patients with kidney disease have disordered bone and mineral metabolism,
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE …
SM Moe, G Chertow, P Parfrey, Y Kubo, G Block… - …, 2015 - iris.unimore.it
Background-Patients with kidney disease have disordered bone and mineral metabolism,
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
[PDF][PDF] Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis
SM Moe, GM Chertow, PS Parfrey, Y Kubo, GA Block… - Circulation, 2015 - Citeseer
Background—Patients with kidney disease have disordered bone and mineral metabolism,
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis
SM Moe, GM Chertow, PS Parfrey, Y Kubo, GA Block… - Circulation, 2015 - cir.nii.ac.jp
< jats: sec>< jats: title> Background—</jats: title>< jats: p> Patients with kidney disease have
disordered bone and mineral metabolism, including elevated serum concentrations of …
disordered bone and mineral metabolism, including elevated serum concentrations of …
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events …
SM Moe, GM Chertow, PS Parfrey, Y Kubo, GA Block… - Circulation, 2015 - dial.uclouvain.be
(eng) BACKGROUND: Patients with kidney disease have disordered bone and mineral
metabolism, including elevated serum concentrations of fibroblast growth factor-23 (FGF23) …
metabolism, including elevated serum concentrations of fibroblast growth factor-23 (FGF23) …
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events …
SM Moe, GM Chertow, PS Parfrey, Y Kubo, GA Block… - 2015 - mediatum.ub.tum.de
Patients with kidney disease have disordered bone and mineral metabolism, including
elevated serum concentrations of fibroblast growth factor-23 (FGF23). These elevated …
elevated serum concentrations of fibroblast growth factor-23 (FGF23). These elevated …
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events …
SM Moe, GM Chertow, PS Parfrey, Y Kubo, GA Block… - Circulation, 2015 - europepmc.org
Background Patients with kidney disease have disordered bone and mineral metabolism,
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE …
SM Moe, GM Chertow, PS Parfrey, Y Kubo… - …, 2015 - iris.unicampania.it
Background. Patients with kidney disease have disordered bone and mineral metabolism,
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …
including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These …